GeneDx
GeneDx's revenue rose 40.0% to $428 million in fiscal 2025. Its operating margin was −3.1%, up from −7.6% a year earlier. Free cash flow was $14 million. The diluted share count rose 6.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What GeneDx does
GeneDx is a genetic testing company that began in 2000 with scientists from the National Institutes of Health. Its main work is exome and genome sequencing, tests that read a person's genes broadly to find the cause of a disease, mostly rare diseases in children. Older panel tests look only at a preset list of genes, based on a doctor's first guess. The company says broad sequencing is moving closer to the standard of care.
Doctors order the tests for patients, and the company reports results back. Payment comes from third parties, such as private health insurers, managed care organizations and government health plans, so the prices they agree to matter a great deal to it. It has also built a large database of rare disease data, called GeneDx Infinity, which it uses to interpret results and says helps its research and discovery work.
It uses automation and artificial intelligence in reading and reporting genetic variants. The company says it is shaping its business around the idea that exome and genome tests will become the routine way to diagnose genetic disease.
Its biggest risks, as it describes them
- Not getting enough doctors and patients to keep ordering its tests.
- Insurers and government plans paying too little, or changing their fee schedules, for its tests.
- A history of net losses since it began.
- Competitors or newer technologies that could make its tests less competitive.
- Losing laboratory capacity to a disaster, or failing to meet laboratory licensing rules.
Income statement
GeneDx lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 401 | 124 | 130 | 141 | 171 |
| Debt incl. finance leases | 11 | 30 | 76 | 75 | 72 |
| Net debt (negative means net cash) | −390 | −94 | −54 | −66 | −99 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.3x | 0.3x | 0.2x |
| Interest coverage | −157.4x | −208.2x | −59.4x | −3.5x | −2.0x |
| Current ratio | 4.8x | 1.5x | 3.1x | 3.6x | 2.5x |
| Quick ratio | 4.4x | 1.4x | 3.0x | 3.4x | 2.3x |
Cash flow
Projections
Project GeneDx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What GeneDx says to expect
- Full year 2026: revenue
Reiterating full year 2026 revenue guidance of $475 to $490 million
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 3 insiders bought $106.6 million of GeneDx shares on the open market, and 4 insiders sold $21.5 million, $510,879 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Katherine StuelandChief Executive Officer, Director | Sold | 10,501 | $97.61 | $1.0 million | Form 4 |
| Sep 16, 2026 | Kevin FeeleyChief Financial Officer | Sold | 3,728 | $97.61 | $363,898 | Form 4 |
| Sep 9, 2026 | Katherine StuelandChief Executive Officer, Director | Sold | 3,692 | $84.22 | $310,940 | Form 4 |
| Sep 9, 2026 | Kevin FeeleyChief Financial Officer | Sold | 1,285 | $84.22 | $108,223 | Form 4 |
| Sep 1, 2026 | Kevin FeeleyChief Financial Officer | Sold | 372 | $83.84 | $31,188 | Form 4 |
| Jun 16, 2026 | Katherine StuelandChief Executive Officer, Director | Sold | 10,501 | $60.76 | $638,092 | Form 4 |
| Jun 16, 2026 | Kevin FeeleyChief Financial Officer | Sold | 3,729 | $60.76 | $226,592 | Form 4 |
| Jun 9, 2026 | Katherine StuelandChief Executive Officer, Director | Sold | 3,639 | $53.77 | $195,669 | Form 4 |
| Jun 9, 2026 | Kevin FeeleyChief Financial Officer | Sold | 1,266 | $53.77 | $68,073 | Form 4 |
| Jun 5, 2026 | Eli CasdinDirector, 10% owner | Bought | 50,000 | $52.86 | $2.6 million | Form 4 |
| Jun 4, 2026 | Eli CasdinDirector, 10% owner | Bought | 150,000 | $56.44 | $8.5 million | Form 4 |
| Jun 1, 2026 | Kevin FeeleyChief Financial Officer | Sold | 369 | $51.74 | $19,092 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 6 of 9 |
| Rule of 40 | −105.2% | 39.7% | 43.3% |
| Altman Z'' | −9.83 | −7.17 | −5.22 |
| Accruals ratio | 1.0% | −5.7% | −11.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 5 of 9 | 6 of 9 |
Compare
Put GeneDx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | |
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | Compare |
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | Compare |
| Veracyte | FY25 | 16.0% | 11.2% | 24.5% | 6.1% | −4.6x | 6 | Compare |
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 196 | 179 | 212 | 235 | 203 | 305 | 428 |
| Revenue growth | — | −8.6% | 18.3% | 10.6% | −13.7% | 50.8% | 40.0% |
| Gross profit | 83 | 4 | −17 | −27 | 90 | 194 | 298 |
| Research and development | 35 | 73 | 105 | 86 | 58 | 46 | 72 |
| Operating income | −30 | −242 | −446 | −668 | −181 | −23 | −13 |
| Net income | −30 | −241 | −245 | −549 | −176 | −52 | −21 |
| Diluted EPS (US$) | −264,056.00 | −47,036.00 | −2.27 | −53.63 | −7.23 | −1.94 | −0.73 |
| Diluted shares (millions) | 0 | 0 | 108 | 10 | 24 | 27 | 29 |
| Cash flow | |||||||
| Cash from operations | −19 | −93 | −190 | −319 | −180 | −28 | 33 |
| Capital expenditure | 12 | 24 | 9 | 7 | 5 | 6 | 19 |
| Free cash flow | −31 | −117 | −200 | −326 | −185 | −34 | 14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 127 | 12 | 0 | 0 |
| Stock-based compensation | 6 | 120 | 219 | 42 | −0 | 9 | 32 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 115 | 108 | 401 | 124 | 130 | 141 | 171 |
| Debt incl. finance leases | — | 21 | 11 | 30 | 76 | 75 | 72 |
| Total assets | — | 252 | 554 | 491 | 419 | 419 | 524 |
| Total liabilities | — | 247 | 166 | 237 | 191 | 174 | 216 |
| Shareholders' equity | −89 | −330 | 388 | 254 | 228 | 245 | 308 |
| Margins and ratios | |||||||
| Gross margin | 42.2% | 2.2% | −7.8% | −11.4% | 44.4% | 63.6% | 69.7% |
| Operating margin | −15.5% | −134.9% | −210.2% | −284.5% | −89.2% | −7.6% | −3.1% |
| Net margin | −15.1% | −134.6% | −115.6% | −233.9% | −86.8% | −17.1% | −4.9% |
| Free cash flow margin | −15.6% | −65.4% | −94.2% | −139.0% | −91.5% | −11.1% | 3.3% |
| Rule of 40 (growth + FCF margin) | — | −74.0% | −75.8% | −128.4% | −105.2% | 39.7% | 43.3% |
| Return on capital | — | — | — | −665.3% | −85.4% | −10.4% | −5.3% |
| Return on equity | — | — | −845.4% | −171.1% | −73.0% | −22.1% | −7.6% |
| Return on assets | — | — | −60.9% | −105.1% | −38.6% | −12.5% | −4.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — |